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Scott L. Parker1, Matthew J. McGirt1, Jeffrey A. Murphy2, J. Thomas Megerian3, Michael Stout2, Luella Engelhart3-BACKGROUND: Cerebrospinal fluid (CSF) shunt infection is a major cause of
morbidity and mortality in the treatment of hydrocephalus and is associated with
significant medical cost. Several studies have demonstrated the efficacy of
antibiotic-impregnated (AI) shunt catheters in reducing CSF shunt infection;
however, providers remain reluctant to adopt AI catheters into practice because
of the increased upfront cost. The objective of this study was to determine if the
use of AI catheters provided cost savings in a large nationwide database.
-METHODS: Hospital discharge and billing records from the Premier Perspec-
tive Database from 2003e2009 were retrospectively reviewed to identify all adult
and pediatric patients undergoing de novo ventricular shunt placement. The
incidence of shunt infection within 1 year of implantation was determined. Shunt
infectionerelated cost was defined as all inpatient billing costs incurred during
hospitalization for treatment of shunt infection.
-RESULTS: In 287 U.S. hospitals, 10,819 adult (AI catheters, 963; standard cath-
eters, 9856) and 1770 pediatric (AI catheters, 229; standard catheters, 1541) patients
underwent ventricular shunt placement. AI catheters were associated with sig-
nificant reduction in infection for both adult (2.2% vs. 3.6%, P[ 0.02) and pediatric
(2.6% vs. 7.1%, P < 0.01) patients. Total infection-related costs were $17,371,320
($45,714  $49,745 per shunt infection) for adult patients and $6,508,064 ($56,104
$65,746 per shunt infection) for pediatric patients. Infection-related cost per 100 de
novo shunts placed was $120,534 for AI catheters and $162,659 for standard
catheters in adult patients and $165,087 for AI catheters and $395,477 for standard
catheters in pediatric patients.
-CONCLUSIONS: In analysis of this large, nationwide database, AI catheters
were found to be associated with a significant reduction in infection incidence,
resulting in tremendous cost savings. AI catheters were associated with a cost
savings of $42,125 and $230,390 per 100 de novo shunts placed in adult and
pediatric patients, respectively.
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Despite improvements in perioperative
antibiotic therapy and surgical technique,
shunt infection remains the most morbid
and ﬁnancially signiﬁcant complication
associated with the treatment of hydro-
cephalus in both pediatric and adult patients
(3, 11, 15, 26). Several independent risk fac-
tors have been identiﬁed, including patient
age, etiology of hydrocephalus, duration of
surgery, revision surgery, surgeon experi-
ence, previous shunt infection, post-
operative cerebrospinal ﬂuid (CSF) leakage,
and external ventricular drainetoeshunt
conversions (22). Ventricular shunt infection
is a common complication, occurring in
3%e15% of patients (2, 4-6, 9, 20, 21, 23).
This complication can be associated with
signiﬁcantmorbidity, including reduced IQ,
psychomotor retardation, seizures, and
shunt failure (1, 5, 11, 13, 33, 35, 36). Shunt
infection is also associatedwith a signiﬁcant
ﬁnancial impact; the average hospital cost
for the treatment of shunt infectionhas been
reported to be approximately $50,000, rep-
resenting the most costly implant-related
infection in the United States (3, 11, 26). The
CC BY-NC-ND license.382 www.SCIENCEDIRECT.comdirect medical cost of shunt infection has
been shown to be $17,300e$48,454, with an
estimated total annual cost of $100 million
(3, 13, 31, 33).
Antibiotic-impregnated (AI) catheters
have been introduced with the primary
objective of reducing the incidence of shunt-
related infections.AI catheters slowly release
antibiotics over several weeks to prevent
the colonization of shunt systems by gram-
positive bacteria, which account for most
shunt infections (7, 14, 22, 24, 27, 32). The
bulk of the literature to date has demon-
strated a reduction in shunt-associated
infections associated with the use of AIWORLD NEUROSURGERY, http://catheters; however, there has been some
reluctance to adopt these systems because of
their increased cost compared with conven-
tional catheters (10, 13, 16, 17, 25, 29). We
assessed the overall costs associated with
shunt infection in a nationwide database to
determine whether the use of AI shunt
catheters is cost saving.METHODS
Data Source
This was a retrospective longitudinal anal-
ysis of hospital discharge and billingdx.doi.org/10.1016/j.wneu.2014.06.010
Table 1. Patient and Hospital Characteristics for Adult Patients Receiving
Antibiotic-Impregnated and Standard Shunt Catheters
Antibiotic-Impregnated Catheter Standard Catheter P Value
Patient characteristics
Age (years) 64.4  18.0 62.5  17.7 < 0.01*
Male (%) 50.2 50.6 0.80
White (%) 77.1 68.8 < 0.01
Number of diagnoses 12.6  8.2 11.6  7.8 < 0.01y
Hospital characteristics
Private (%) 25.3 29.9 0.01
>500 beds (%) 68.5 52.8 < 0.01
Academic (%) 39.5 58.0 < 0.01
Southern region (%) 66.7 45.9 < 0.01
Mean  SD. P values are from c2 test except where noted.
*Student t test.
ySatterthwaite t test.
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Perspective Database, a hospital service
database that includes detailed patient-
level data from inpatient hospitalizations
and hospital outpatient visits. This data-
base includes information from >600 U.S.
hospitals with information pertaining to
patient demographics (age, sex, race),
hospital characteristics, principal and sec-
ondary diagnoses, payer, cost of care,
medication utilization, departmental cost
and charge detail, length of stay, and
physician specialty (8). Participating hos-
pitals submit data to the Premier Perspec-
tive Database on a monthly or quarterly
basis. The data undergo multiple, separate
quality assurance and data validation
checks before they are made available for
research purposes. All data are deidentiﬁed
in accordance with the Health Insurance
Portability and Accountability Act.
Patient Population
All adult and pediatric (17 years old,
excluding neonates) patients undergoing
de novo ventricular shunt placement be-
tween April 2003 and July 2009 were
included in this study. Neonates were
excluded from analysis secondary to a lack
of statistical comparison power for this age
group. Patients were identiﬁed by the In-
ternational Classiﬁcation of Diseases, 9th
Edition, procedure code 02.34 (placement
of a ventricular shunt to abdominal cavity
and organs). Patients in the AI cohort
received both ventricular and distal AI
catheters. Patients in the standard cohort
received no AI catheters of any type. Addi-
tionally, it was conﬁrmed that the patients
had undergone no shunting procedures in
the prior 2 years. The hospitalization for the
initial placement of the shunt was deﬁned
as the index hospitalization.
Definition of Shunt Infection and Cost
Calculation
Shunt infection was deﬁned as a hospital
claim with an infection diagnosis code of
996.63 (infection and inﬂammatory reaction
due to nervous system device, implant, and
graft electrodes implanted in brain) within 1
year after the initial shunt insertion proce-
dure and 1 or both of the following: 1) shunt
revision International Classiﬁcation of Dis-
eases, 9th Edition, procedure code (02.2,
02.3, 02.32, 02.35, 02.39, 02.4, 02.41, 02.42,
02.43, 54.95) within 1 year of the 996.63 code
and 2) 5 consecutive days of any of theWORLD NEUROSURGERY 83 [3]: 382-386following antibiotics within 7 days before or
after the 996.63 infection code: ceftriaxone,
ceftazidime, cefotaxime, ceftizoxime, van-
comycin, gentamicin, linezolid, cefepime,
meropenem, or ciproﬂoxacin. Time to shunt
infection was measured from the date of
index shunt implantation to the ﬁrst occur-
rence of the infection-related elementwithin
the ﬁrst year. For the purposes of this study,
shunt infectionerelated cost was deﬁned
as all inpatient billing cost incurred during
the hospitalization for treatment of shunt
infection. This cost calculation also included
the cost difference of AI versus standard
catheters.
Statistical Analysis
All analyses were performed using SAS
version 9.3 (SAS Institute, Inc, Cary, North
Carolina, USA). Summary data were pre-
sented as mean  SD for parametric data.
Nonparametric data were presented as me-
dian [interquartile range]. Percentages were
compared via chi-square or Fisher exact test
for intergroup comparison. Student t-test
was used for parametric data, andWilcoxon
rank sum test was used for nonparametric
data.RESULTS
Overall Population
During the reviewed period, 12,589
consecutive adult and pediatric patients, MARCH 2015 wwfrom 287 hospitals undergoing de novo
ventricular shunt placement were identi-
ﬁed. There were 496 (3.9%) patients
identiﬁed who experienced and received
treatment for a shunt infection within 1
year of the index shunt placement. The
median [interquartile range] time to shunt
infection was 4.6 [4.1e13.3] weeks. The
total cost associated with treatment of
shunt infections was $23,879,424 ($48,144
 $54,021 per shunt infection).Adult Population
Adult patient and hospital characteristics
for the AI and standard catheter groups
are listed in Table 1. During the reviewed
time period, 10,819 adult patients were
identiﬁed who underwent a de novo shunt
placement. Of these, 380 (3.5%) patients
experienced a shunt infection within 1 year
of placement. The total cost associated with
treatment of shunt infection within the
adult population was $17,371,320 ($45,714
 $49,745 per shunt infection) (Table 2).
AI shunt catheters were placed in 963
(8.9%) adult patients, and standard shunt
catheters were placed in 9,856 (91.1%) pa-
tients. A shunt infection was experienced by
21 (2.2%) patients with AI catheters versus
359 (3.6%) patients with standard catheters
(P ¼ 0.02). There was no difference in time
to shunt infection between the AI and stan-
dard catheter cohorts (8.6 [0.1e17.7] weeks
vs. 4.6 [4.3e13.3] weeks; P ¼ 0.29). Thew.WORLDNEUROSURGERY.org 383
Table 2. Incidence and Cost of Shunt Infections for Antibiotic-Impregnated and Standard Shunt Catheters in the Adult Population
Number of
Patients
Number of Shunt
Infections
Incidence Shunt
Infection
Median Time to
Shunt Infection
Total
Shunt-Related Cost
Mean Cost per
Shunt Infection
Infection Cost per
100 De Novo Shunts
AI catheters 963 21 2.2% 8.6 weeks $1,150,548 $54,788  $59,728 $120,534
Standard
catheters
9856 359 3.6% 4.6 weeks $16,220,697 $45,183  $49,146 $162,659
AI, antibiotic-impregnated.
Table 3. Comparison of Patient and Hospital Characteristics for Pediatric Patients
Receiving Antibiotic-Impregnated and Standard Shunt Catheters
Antibiotic-Impregnated Catheter Standard Catheter P Value
Patient characteristics
Age (years) —* —*
Male (%) 50.2 54.7 0.20
White (%) 59.8 54.3 0.11
Number of diagnoses 9.1  8.5 8.1  7.8 0.06y
Hospital characteristics
Private (%) 41.5 40.0 0.16
>500 beds (%) 38.0 67.4 < 0.01
Academic (%) 75.6 73.2 0.45
Southern region (%) 76.0 66.3 < 0.01
Mean  SD. P values are from c2 test except where noted.
*Patient age <15 years unavailable because of the Health Insurance Portability and Accountability Act.
yStudent t test.
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the AI cohort and $16,220,697 for the stan-
dard catheter cohort. The mean cost per
shunt infection was similar for patients in
the AI ($54,788  $59,728) and standard
($45,183  $49,146) catheter cohorts (P ¼
0.39). The infection-related cost per 100 de
novo shunts placed (infection incidence
multiplied by mean infection-related cost)
was $120,534 for AI catheters and $162,659
for standard shunt catheters. The use of AI
catheters was associated with an infection-
related cost savings of $42,125 per 100 de
novo shunts placed (Table 2).
Pediatric Population
Pediatric patient and hospital characteristics
for the AI and standard catheter groups are
listed in Table 3. During the reviewed time
period, 1770 pediatric patients were identi-
ﬁed who underwent a de novo shunt
placement. Of these, 116 (6.6%) patients
experienced a shunt infectionwithin 1 year of
placement. The total cost associated
with treatment of shunt infection within
the pediatric population was $6,508,064
($56,104  $65,746 per shunt infection)
(Table 4).
AI shunt catheters were placed in 229
(12.9%) pediatric patients compared with
1541 (87.1%) patients who had standard
shunt catheters placed. A shunt infection
occurred in 6 (2.6%) patients in the AI
catheter cohort versus 110 (7.1%) patients in
the standard catheter cohort (P < 0.01).
There was no difference in time to shunt
infection between the AI and standard
catheter cohorts (13.3 [0.1e30.7] weeks vs.
4.6 [0.7e17.6] weeks; P ¼ 0.29). The infec-
tion-related cost totaled $380,970 for the AI
cohort and $6,127,110 for the standard
catheter cohort. The mean cost per shunt
infection was similar for patients in the
AI ($63,495  $69,968) and standard
($55,701  $65,824) catheter cohorts (P ¼
0.78) (Table 4). The infection-related cost per384 www.SCIENCEDIRECT.com100 de novo shunts placed was $165,087 for
AI catheters and $395,477 for standard shunt
catheters. The use of AI catheters was asso-
ciated with an infection-related cost savings
of $230,390 per 100 de novo shunts placed.DISCUSSION
In the analysis of this large, nationwide
database containing data from 287 hospi-
tals and 12,589 consecutive patients un-
dergoing placement of a de novo ventricular
shunt, AI catheters were associated with a
1.4% (P ¼ 0.02) and 4.5% (P < 0.01) abso-
lute reduction in infection for adult and
pediatric populations, respectively. The
reduction in infection associated with the
use of AI catheters also resulted in cost
savings for both adult and pediatric co-
horts. For adults, use of AI catheters was
associated with an infection-related cost
savings of $42,125 per 100 de novo shunts
placed. The cost savingswasmore dramaticWORLD NEUROSURGERY, http://in the pediatric cohort, with use of AI
catheters being associated with an infec-
tion-related cost savings of $230,390 per
100 de novo shunts placed. The results of
this analysis suggest that AI catheters pro-
vide signiﬁcant cost savings when used for
the treatment of hydrocephalus in both
adult and pediatric cohorts.
Shunt infection is one of the most com-
mon etiologies of shunt-related complica-
tions, with a rate of 3%e15% as described
by systematic reviews of the literature (24,
34). Previous studies have identiﬁed a
multitude of independent risk factors
associated with shunt infection, including
length of surgery, number of prior re-
visions, experience of the surgeon, etiology
of hydrocephalus, patient age, immune
status, and postoperative CSF leakage
(1, 10, 12, 18, 19, 27, 28, 30). Despite
continued improvements in surgical and
sterilization technique, perioperative anti-
biotic therapy, and appreciation of thedx.doi.org/10.1016/j.wneu.2014.06.010
Table 4. Incidence and Cost of Shunt Infections for Antibiotic-Impregnated and Standard Shunt Catheters in the Pediatric Population
Number of
Patients
Number of Shunt
Infections
Incidence Shunt
Infection
Median Time to
Shunt Infection
Total
Shunt-Related Cost
Average Cost per
Shunt Infection
Infection Cost per
100 De Novo Shunts
AI catheters 229 6 2.6% 13.3 weeks $380,970 $63,495  $69,968 $165,087
Standard
catheters
1541 110 7.1% 4.6 weeks $6,127,110 $55,701  $65,824 $395,477
AI, antibiotic-impregnated.
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reductions in infection rates remain elusive
(10). Shunt-associated infections prolong
in-hospital stays and lead to signiﬁcant
morbidity andmortality, with 33%of shunt-
related deaths occurring secondary to shunt
infection (13, 26, 31, 37).
The literature to date contains multiple
studies demonstrating a reduction in shunt
infection associated with the use of AI
catheters. A systematic literature review
showed AI catheters to be associated with a
signiﬁcant infection reduction overall
(3.3% vs. 7.2%), for adult-speciﬁc cohorts
(0.9% vs. 5.8%), and for pediatric-speciﬁc
cohorts (5.0% vs. 11.2%) (24). The results of
the current study further corroborate the
ﬁndings from the literature as a whole. This
infection reduction has previously been
shown to result in signiﬁcant cost savings.
Attenello et al. (3) demonstrated that the
introduction of AI catheters into their
institutional practice resulted in signiﬁcant
hospital cost savings for pediatric patients.
The authors reported that although mean
hospital cost per shunt infection was
similar for AI and standard catheters, the
infection-related hospital cost per 100 pa-
tients receiving shunts was markedly lower
in the AI cohort versus standard cohort
($151,582 vs. $593,715) because of the
decreased incidence of shunt infection in
the AI cohort. A similar cost savings has
been demonstrated in the adult population.
Farber et al. (15) reported that AI shunt
catheters were associated with a direct cost
savings of $47,193 per 100 shunt surgeries
performed. The reluctance of providers and
health care systems to adopt AI catheters
into routine practice has largely been sec-
ondary to the direct initial cost of these
systems. Each AI catheter costs approxi-
mately $400.00 more than a standard
shunt catheter, which can represent a
signiﬁcant upfront cost in high-volumeWORLD NEUROSURGERY 83 [3]: 382-386centers (13, 26). However, when consid-
ering the signiﬁcant cost savings associated
with the reduction in infection reported
here, AI shunt catheters may be extremely
cost-effective.
Analyses of large, administrative data-
bases such as this one can provide valuable
information but have inherent limitations
with regard to determination of causality.
As with all retrospective analyses, it was not
possible to control completely for patient
and surgeon characteristics that may affect
the selection of treatment or the risk of
infection. The neonate population could not
be assessed with this data set because of an
insufﬁcient number of patients to compare.
Because neonates are at particular risk for
CSF infection, further studies are warranted
to better understand this patient cohort. The
costs reported here represent only inpatient
hospitalization costs and are limited to
charges occurring within 1 year after the in-
dex shunt procedure. Costs after discharge,
such as home health, rehabilitation, missed
work, and lost productivity, were not
assessed in the current study, and these
factors can contribute a signiﬁcant compo-
nent to the overall costs of treatment in this
patient population. It is also possible that
infection occurred beyond the 1-year follow-
up period for this study. All of these factors
would increase further the costs associated
with CSF infections in this patient popula-
tion. Although randomized controlled trials
remain the “gold standard” for assessing
safety and efﬁcacy and would control for
potential catheter selection bias inherent in
an observational study, administrative data-
bases provide the ability to assess multiple
risk factors and the association of different
treatments with clinical and economic out-
comes among extremely large cohorts.
Results from large population studies are
more likely to be generalizable to the average
patient undergoing these procedures., MARCH 2015 wwCONCLUSIONS
In analysis of a large, nationwide database,
AI catheters were found to be associated
with a signiﬁcant reduction in incidence of
infection, resulting in cost savings. AI
catheters were associated with a cost sav-
ings of $42,125 and $230,390 per 100 de
novo shunts placed in adult and pediatric
patients, respectively.
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